TECHWIRE 30
(CIX: WRAL30)  1,094.59    (0 %)  Updated: 08:10 PM EDT, Jul 29 2014
(NQ: Apple)  98.38    (0 %)  Updated: 08:10 PM EDT, Jul 29 2014
(NY: QUINTILES)  55.94    (0 %)  Updated: 06:40 PM EDT, Jul 29 2014
(OP: BASF SE)  108.47    (0 %)  Updated: 08:10 PM EDT, Jul 29 2014
(NQ: BioCryst)  12.25    (0 %)  Updated: 08:10 PM EDT, Jul 29 2014
(NQ: BioDelivery)  13.05    (0 %)  Updated: 08:10 PM EDT, Jul 29 2014
(NQ: CEMP)  9.70    (0 %)  Updated: 08:10 PM EDT, Jul 29 2014
(NQ: Cisco Systems)  25.71    (0 %)  Updated: 08:10 PM EDT, Jul 29 2014
(NQ: Cree)  48.25    (0 %)  Updated: 08:10 PM EDT, Jul 29 2014
(NQ: DARA)  1.33    (0 %)  Updated: 08:10 PM EDT, Jul 29 2014
(NY: EMC CORPORATION)  29.47    (0 %)  Updated: 06:40 PM EDT, Jul 29 2014
(NQ: Extreme Networks)  4.79    (0 %)  Updated: 08:10 PM EDT, Jul 29 2014
(NQ: FB)  73.71    (0 %)  Updated: 08:10 PM EDT, Jul 29 2014
(NY: GLAXOSMITHKLINE)  48.03    (0 %)  Updated: 06:40 PM EDT, Jul 29 2014
(NQ: GOOG)  585.61    (0 %)  Updated: 08:10 PM EDT, Jul 29 2014
(NY: IBM)  194.57    (0 %)  Updated: 06:40 PM EDT, Jul 29 2014
(NY: LH)  105.38    (0 %)  Updated: 06:40 PM EDT, Jul 29 2014
(OP: Lenovo Group)  27.70    (0 %)  Updated: 08:10 PM EDT, Jul 29 2014
(NY: MRK)  58.58    (0 %)  Updated: 06:40 PM EDT, Jul 29 2014
(NQ: Microsoft Corp)  43.89    (0 %)  Updated: 08:10 PM EDT, Jul 29 2014
(NQ: NTAP)  38.58    (0 %)  Updated: 08:10 PM EDT, Jul 29 2014
(NY: NOVARTIS AG)  88.21    (0 %)  Updated: 06:40 PM EDT, Jul 29 2014
(OP: Novozymes A/S)  50.44    (0 %)  Updated: 08:10 PM EDT, Jul 29 2014
(NY: PFIZER)  29.73    (0 %)  Updated: 06:40 PM EDT, Jul 29 2014
(NQ: Pozen)  7.28    (0 %)  Updated: 08:10 PM EDT, Jul 29 2014
(NY: RED HAT)  56.15    (0 %)  Updated: 06:40 PM EDT, Jul 29 2014
(NQ: BBRY)  9.51    (0 %)  Updated: 08:10 PM EDT, Jul 29 2014
(NQ: Salix)  131.48    (0 %)  Updated: 08:10 PM EDT, Jul 29 2014
(NQ: SQI)  15.11    (0 %)  Updated: 08:10 PM EDT, Jul 29 2014

Posts tagged “Salix”

July 17

Salix wins FDA approval for drug to treat rare genetic disorder

Salix Raleigh-based Salix Pharmaceuticals has received FDA approval for a drug to treat a rare genetic disorder called hereditary angloedema.

Updated July 10

Premium Lock Salix stock sags despite merger deal that boosts drug pipeline, lowers tax rate

If investors are fretting, it could be because Salix shareholders will be on the hook for taxes they weren't expecting to pay. The company notes in its securities filings that the conversion of Salix stock into Salix plc stock is considered a taxable event, meaning all Salix shareholders will owe taxes when the deal closes even if they don't sell their shares. Learn more about the deal.

Salix Salix

July 9

Salix to merge with Ireland unit of Cosmo Pharma in stock deal

Salix Pharmaceuticals (NASDAQ:SLXP) is merging with a subsidiary of Italian drug company Cosmo Pharmaceuticals in a deal that brings Salix new drug products and also reduces the Raleigh company's taxes.

Salix Salix

Updated February 27

Premium Lock Salix strikes $12M licensing deal for bowel prep drug

Salix Raleigh-based Salix Pharmaceuticals, which focuses on gastrointestinal treatments, is adding another product to its lineup. Salix is committing $12 million plus royalties to RedHill Biopharma for a bowel prep drug.

February 25

Premium Lock Salix prevails in $150M suit filed by drug partner

Salix In a legal fight dating to 2011, Raleigh-based Salix Pharmaceuticals has won a jury decision that throws out a lawsuit filed against it by drug partner Napo Pharmaceuticals.

January 30

Premium Lock FDA accepts new drug filing for Salix rectal inflammation drug

Salix A proposed treatment for a difficult to threat form of rectal inflammation licensed by Salix Pharmaceuticals is moving closer to approval by the FDA.

Updated January 14

Premium Lock Expanding Salix sales force expected to grow drug sales to $1.6B in 2014

Salix Salix Pharmaceuticals expects it will reach $1.6 billion in total product revenue this year. WRALtechWire Insiders can read more details on the gastrointestinal pharma's projections following the close of its $2.8 billion acquisition of Santarus as its stock hits a new record high.

January 3

Premium Lock Salix closes on $2.6B deal for San Diego pharma Santarus

Salix, a specialty pharmaceutical company focused on gastrointestinal treatments, said it will acquire all of the outstanding common stock of Santarus at the price of $32 per share, a 37.9 premium over the company's Thursday closing price of $23.20

Salix Salix

Updated November 7, 2013

Premium Lock Salix to acquire San Diego pharma Santarus for $2.6B

Salix, a specialty pharmaceutical company focused on gastrointestinal treatments, said it will acquire all of the outstanding common stock of Santarus at the price of $32 per share, a 37.9 premium over the company's Thursday closing price of $23.20

Salix Salix

August 8, 2013

Premium Lock Salix CEO Logan talks about M&A strategy

Salix Even though Salix Pharmaceuticals has diversified its portfolio of gastrointestinal drug treatments, CEO Carolyn Logan says Salix is always looking for deals. Read what she has to say about Salix's acquisition strategy.

Updated June 11, 2013

Premium Lock Salix constipation drug Relistor to go before FDA advisory panel

Salix Salix Pharmaceuticals' (NASDAQ:SLXP) constipation drug Relistor, which failed to win regulatory approval last year, will be up for review by a FDA advisory committee.

May 22, 2013

Premium Lock Salix rectal inflammation drug shows positive clinical trial results

Salix Salix Pharmaceuticals' topical foam to treat rectal inflammation could be filed for approval with the Food and Drug Administration by the end of September.

Updated May 10, 2013

Premium Lock Prescription growth lifts Salix's 1Q sales

Salix First quarter sales of Salix Pharmaceuticals' top drug, Xifaxan, increased 18 percent year over year. Read more about the company's performance.

Updated May 10, 2013

Premium Lock FDA makes Salix wait on constipation drug; company says no new trials needed

Salix The FDA said it needed more data to approve expanded use of Salix Pharmaceutical's constipation drug Relistor. Read why Salix thinks it has enough information.

Updated March 6, 2013

Premium Lock Salix CEO gears for federal probe that could go on for 'quite some time'

Salix Carolyn Logan, chief executive officer at Raleigh-based Salix pharmaceuticals, and the company are gearing up for what could be a lengthy federal investigation into its marketing practices.

Updated February 15, 2013

Premium Lock Feds subpoena Salix, ask about drug promotion practices

Salix Federal prosecutors have questions about how Salix Pharmaceuticals (NASDAQ:SLXP) sells and promotes its drugs, including its top-selling product Xifaxan.

January 3, 2013

Premium Lock Drug approval sends Salix shares up nearly 5%

Salix Shares in Salix Pharmaceuticals rose nearly 5 percent Wednesday on news that the FDA had approved its new drug for the treatment of AIDS-related diarrhea.

January 2, 2013

Premium Lock FDA approves new Salix drug to treat AIDS-related diarrhea

Salix Shares in Salix Pharmaceuticals rose more than 3 percent Wednesday on news that the FDA had approved its new drug for the treatment of AIDS-related diarrhea.

November 8, 2012

Premium Lock Earnings: Salix; PowerSecure; Pozen; BioCryst

Bulldog Inside the Bulldog Blog: Revenues up at Salix; record revenues for PowerSecure; Pozen cuts losses; net loss declines at Biocryst;

Updated October 23, 2012

Premium Lock Raleigh drug firm Salix sponsors documentary on liver disease

Salix Pharmaceuticals and the American Liver Foundation back a new documentary about hepatic encephalopathy, or HE, which was directed by Academy Award winner Cynthia Wade.

Salix backs "HE" documentary Salix backs "HE" documentary

Techwire Inside Partners
The Skinny: A Blog by Rick Smith

OUR INSIDERS

Vivek Wadhwa
Commentary
Dr. Mike Walden
Tech economy
Frank Vinluan
Life science
Scroll